Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1a of XW001 in healthy adults
NCT05642403Phase 1Completed
- Sponsor
- Sciwind Biosciences
- Start
- Jan 2021
- Primary completion
- Jun 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of xw001 in respiratory syncytial virus infection (RSV) (4 cohorts), sponsored by Sciwind Biosciences. Primary endpoint: Safety/tolerance endpoints at 42 Days. Started Jan 2021; status: completed.
02
Drugs
xw001
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT05642403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05642403.